In 1914, Theodor Boveri postulated that the reason of malignant cell growth is based on a nonrepairable cellular defect located in the nucleus of cells (Boveri, 1914) . He suggested that these defects are of chromosomal origin that lead to the downregulation of growth-inhibitory signals and elevation of divisionpromoting signals. Thus, Boveri described for the first time the antagonistic action of signals contributing to differentiation and proliferation. Furthermore, he concluded that every tumor cell originates from a single mother cell. Up to date his hypotheses are still valuable and were further supported by the identification of oncogenes and tumor suppressor genes that trigger neoplastic development. The best example for the accumulation of genetic alterations as a driving force for neoplastic development comes from the analyses of colon carcinomas. It has been shown that oncogenesis is a multistep process, which requires subsequent accumulation of three to seven genetic defects in colon carcinomas (Vogelstein and Kinzler, 1993) . Another example is the deregulation of the Wnt/b-catenin pathway initiated by mutations in the adenomatous polyposis coli gene, which are often found in colon carcinomas (Munemitsu et al., 1995; Rubinfeld et al., 1996) . Tumors derived from different origin vary in the way they accumulate genetic lesions. While defects of p53 are common in the majority of human tumors, mutations in the genes coding for the breast cancer susceptibility proteins 1 and 2 (BRCA1 and BRCA2) are primarily found in breast cancer. Despite different types of genetic lesions in human cancer, a common feature of all tumor cells is a high proliferation rate. In this review, we shall focus on the role of Polo-like kinases (Plks) for cellular proliferation and oncogenic transformation.
Polo-like kinases
Plks belong to the family of mitotic serine/threonine kinases, which are highly conserved among eukaryotes. Four Plks have been identified to date in mammalian cells: Plk1, Plk2/Snk, Plk3/Fnk/Prk (proliferation-related kinase) and Plk4/Sak (Simmons et al., 1992; Clay et al., 1993; Lake and Jelinek, 1993; Fode et al., 1994; Golsteyn et al., 1994; Hamanaka et al., 1994; Holtrich et al., 1994 Holtrich et al., , 2000 Li et al., 1996) . Named according to the first identified member of the family, Polo from Drosophila melanogaster, Plks are characterized by a highly conserved N-terminal serine/threonine protein kinase domain and the presence of one or two Cterminal regions of similarity termed the polo boxes (PB). These PB motifs within Cdc5 and Plk1 are required for subcellular localization to mitotic structures and for mitotic progression (Lee et al., 1998) . Moreover, the C-terminus including the PB domain (PBD) is involved in regulating the kinase activity of Plks (Jang et al., 2002) . In Plk1, Plk2 and Plk3, the conserved C-terminal PBD contains two PBs (PB1 and PB2). In contrast, Plk4 encompasses only one PB that contributes to the formation of Plk4 homodimers.
Among the four mammalian Plks, Plk1 is the most thoroughly studied family member. Plk1 homologues were identified as Polo in Drosophila, Cdc5 in Saccharomyces cerevisiae, Plo1 in Schizosaccharomyces pombe and Plx1 in Xenopus. The expression of Plk1 starts in late S phase, leading to the accumulation of Plk1 protein in G 2 and M phase. Its kinase activity peaks during mitosis. At the G 2 /M transition, Plk1 and its homologues (Cdc5 and Plx1) contribute to centrosome maturation (Lane and Nigg, 1996; de Carcer et al., 2001; , bipolar spindle formation (Ohkura et al., 1995) , DNA damage checkpoint adaptation (Sanchez et al., 1999) and to the activation of the MPF (maturation-promoting factor) by phosphorylation of Cdc25C (Abrieu et al., 1998; Qian et al., 1998; Roshak et al., 2000) and cyclin B1 (ToyoshimaMorimoto et al., 2001; Yuan et al., 2002a) . Studies in Xenopus and mammalian cells revealed that in later stages of mitosis, Plx1 and Plk1 are involved in the activation of components of the APC (anaphasepromoting complex) for mitotic exit (Descombes and Nigg, 1998) and in cytokinesis (Mundt et al., 1997; Carmena et al., 1998) . Moreover, Plk1 is inhibited by DNA damage in G 2 and mitosis (Smits et al., 2000) . Thus, the major function of Plk1 and its homologues in different species is the regulation of mitosis and cytokinesis. The process of cell division is controlled by different checkpoints to ensure genetic stability. Plks are known to be involved in the regulation of these checkpoints.
Furthermore, Plk2 and Plk3 represent two immediateearly genes. In contrast to Plk1, mitogenic stimuli induce their expression, suggesting that both kinases have roles outside of mitosis. While Plk2 is expressed predominantly in G 1 (Ma et al., 2003b) , the abundance of human Plk3 remains unchanged throughout the cell cycle. The kinase activity of Plk3 peaks during late S and G 2 phases (Ouyang et al., 1997) . Both kinases, Plk1 and Plk3, associate with components of the mitotic apparatus such as spindle poles, mitotic spindles and mid-body Wang et al., 2002; Dai and Cogswell, 2003) . Like Plk1, Plk3 is able to complement a Cdc5 temperature-sensitive mutation, indicating that both kinases have overlapping functions in mitosis (Lee and Erikson, 1997; Ouyang et al., 1997) . Still, at least at the G 2 /M transition, they might act in an antagonistic manner. Plk1 promotes the G 2 /M transition by phosphorylation of Cdc25C, leading to its activation and nuclear translocation (Roshak et al., 2000; ToyoshimaMorimoto et al., 2002) . In contrast, Plk3 phosphorylates Ser-216 in Cdc25C, thereby creating a binding site for 14-3-3 protein resulting in sequestration of the protein phosphatase in the cytoplasm and leading to the inhibition of Cdc25C activity (Ouyang et al., 1999) . Surprisingly, Plk3 is also able to phosphorylate Cdc25C at Ser-191 to promote its nuclear translocation (Bahassi el et al., 2004) . Diverging results observed for the regulation of Cdc25C by Plk3 might be due to the distinct cellular context: while Plk3-mediated inactivation of Cdc25C occurs after the activation of the DNA damage checkpoint, its activation might be due to the expression of Plk3 in genetically unperturbed cells. Nevertheless, accumulating evidence suggests that Plk3 is an inhibitor of Cdc25C and G 2 /M transition in response to DNA damage (Ouyang et al., 1999; Xie et al., 2002) .
The influence of Plk2 on the cell cycle is barely characterized. Unlike Plk1, Plk2 is not required for cell division but seems to influence the G 1 progression (Ma et al., 2003a) . However, Plk2 is activated by a mitotic checkpoint in a p53-dependent manner and thereby may prevent mitotic catastrophe following spindle damage (Burns et al., 2003) . The fourth member, Plk4, contains only one PB (PB1), which mediates homodimerization of Plk4 (Leung et al., 2002) . It has been described that Plk4 expression is associated with meiotic and mitotic cell division (Fode et al., 1994; Hudson et al., 2001 ).
Roles of Plks in early and late mitotic events
One striking consequence of deregulated Plk1 activity is the formation of aberrant centrosomes and mitotic spindle poles, which are tightly correlated with aneuploidy and chromosomal instability in tumor development. The mitotic functions of Plks are conserved from yeast to mammals. Cdc5 and Plo1, homologues of Plks in budding yeast and fission yeast, respectively, are required for functional spindle pole bodies (SPB) and for the formation of normal mitotic spindles. Good evidence indicating a role for Cdc5 in regulating SPB came from the study of meiosis I in budding yeast (Schild and Byers, 1980) . A temperature-sensitive mutant of Cdc5 fails to complete meiosis I due to arrest at a stage after SPB duplication and separation at the restrictive temperature. In these mutant cells, SPBs lack the normal spindle microtubules that are characteristic for meiosis I in wild-type cells. In fission yeast Plo1 is indispensable for the assembly and function of the mitotic spindle. Both loss of Plo1 function and overexpression of this gene result in the formation of cells in which condensed chromosomes are associated with monopolar spindles (Ohkura et al., 1995) , indicating a failure in bipolar spindle formation. The essential roles of Plks for centrosome maturation were also demonstrated by studies in the fruit fly. Drosophila Polo is also required for cytokinesis as well as for organization of spindle poles. Fruit flies homozygous for the mutated polo allele exhibit abnormalities in spindle poles during development (Sunkel and Glover, 1988) . While in strongly hypomorphic mutants (polo 9/10 ), a majority of cells are arrested in a metaphase-like stage lacking asters at each spindle pole and they all possess bipolar spindles with robust arrays of microtubles (Donaldson et al., 2001) . Beside their functions in yeast and Drosophila, Plks are also indispensable in vertebrates to ensure the proper segregation of the genetic material, because the deregulation of Plks leads to abnormal centrosome organization and genetic instability. In mammals, Plks are involved in regulating centrosomal function. Plk1 was first implicated in the centrosome cycle because of its centrosomal localization during interphase and its association with mitotic spindle poles in early mitosis (Golsteyn et al., 1994) . More appealing evidence comes from antibody microinjection experiments (Lane and Nigg, 1996) . HeLa cells injected with antibodies against Plk1 accumulated as pseudo-mitotic cells, many of which displayed monoastral microtubule arrays reminiscent of the monopolar spindles observed in Drosophila Polo mutants and plo1-deficient fission yeast cells described above. Centrosomes in cells injected with antibodies against Plk1 failed to grow in size, and the recruitment of several proteins to centrosomes was impaired (Lane and Nigg, 1996) . Further intriguing results emerged from experiments using dnPlk1, demonstrating that SAOS-2 and U2OS cells arrested with bipolar anaphase-like spindles or as prophase-like mitotic cells with monoastral arrays emanating from a single organizing center (Cogswell et al., 2000) . The results from both studies were extended by applying siRNAs targeting Plk1 (Spankuch-Schmitt et al., 2002a) . The observations strongly suggest that centrosome maturation is essential for the nucleation of mitotic microtubules. Plks are of vital importance for centrosome maturation, separation and mitotic spindle assembly in late G 2 phase and mitosis. Deregulation of Plks is tightly associated with impaired centrosome size/number, both of which show a tight correlation with aneuploidy and genetic instability. Thus, deregulation of Plks could contribute to tumor development. Further studies will shed more light onto the possible crosstalk between Plk1 and other kinases, for example, Aurora kinases and Cdk1/cyclin B, in context of the functional regulation of centrosome maturation.
Like Plk1, Plk3 is also located at centrosomes during interphase. As the cell cycle progresses through S, G 2 and M phases, Plk3 comigrates with duplicated centrosomes in all stages of the cell cycle . It has been postulated that Plk3 may play a role in controlling centrosomal function during interphase. Furthermore, Warnke and co-workers showed that Plk2 is a centrosomal protein and that its kinase activity is likely to be required for centriole duplication near the G 1 /S transition (Warnke et al., 2004) . Thus, Plks may fulfill different functions in regulating microtubule dynamics during the cell cycle (Dai et al., 2002b; Dai and Cogswell, 2003) . In summary, the orchestration among Plks is likely to be responsible for proper regulation of centrosomes and mitotic spindle poles throughout the cell cycle. Deregulation of Plks could in part contribute to abnormalities of centrosomes.
In mitotic cells, Plks associate with spindle poles and kinetochores, indicating a role for these kinases in kinetochore assembly, kinetochore-microtuble interactions and/or the regulation of the spindle checkpoint. By late anaphase, Plks are found distributed along the midzone of the mitotic spindle. Sister-chromatid separation and mitotic exit are coordinated by APC/C-dependent ubiquitylation and proteolysis that require Plk1 activity (Kotani et al., 1998; Sumara et al., 2002) . The evidence that Plks might play a role in cytokinesis came from the observation that Plk1 colocalizes in living cells with a kinesin-related motor protein known as CHO1/MKLP-1 involved in crosslinking and movement of microtubules (Lee et al., 1995) . Additional evidence came from studies of Plo1 function in fission yeast. Ohkura et al. observed that overexpression of Plo1 causes the formation of multiple septation points in the absence of nuclear division. In contrast, Plo1 mutants undergo successfully nuclear division and subsequently fail to form septal structures such as an F-actin ring (Ohkura et al., 1995) . In contrast, overexpression of Plk1 in HeLa cells generates multinucleation (Mundt et al., 1997) , which is also observed by applying antibodies against Plk1 (Lane and Nigg, 1996) . Taken together, these results revealed that the function of Plks is required for a proper sister-chromatid segregation and cytokinesis. Deregulation of Plks could contribute to phenotypes like multinucleation that is one of the hallmarks in tumorigenesis.
Moreover, expression of hyperactive Plk1 in U2OS cells results in reversion of the G 2 block imposed by DNA damage, indicating that enhanced Plk1 activity is able to over-ride the DNA damage checkpoint (Smits et al., 2000) . Cells that proceed into mitosis despite genetic defects will accumulate genetic alterations followed by oncogenic transformation. Several lines of evidence indicate important roles of Plk1 in controlling M phase and deregulation of Plk1 leads to failure of cytokinesis, further promoting the accumulation of genetic defects (Seong et al., 2002; Neef et al., 2003; Zhou et al., 2003; Liu et al., 2004) . Thus, different lines of evidence suggest that deregulation of Plks contributes to neoplastic transformation.
Plks and cellular proliferation
To promote oncogenesis, the balance between proliferation and differentiation has to be shifted towards proliferation-stimulating signals. Plk1 contributes to pathways, which positively trigger entry into and progression through mitosis. Thus, enhanced Plk1 activity accelerates cellular proliferation at least in M phase. Levels of Plk1 mRNA and protein are significantly increased in proliferating cells (Holtrich et al., 1994; Wolf et al., 2000) . Conversely, in myeloid leukemia cell lines undergoing terminal differentiation, Plk1 expression is drastically reduced (Yuan et al., 1997) . Based on the analysis of numerous types of human tumors and multiple cancer cell lines, Plk1 has been suggested as a marker for proliferation (Yuan et al., 1997) : Elevated Plk1 levels were found in non-small-cell lung cancer , head/neck squamous cell carcinomas (HNSCC) (Knecht et al., 1999) , esophageal carcinoma (Tokumitsu et al., 1999) , oropharyngeal carcinomas (Knecht et al., 2000) , melanomas , breast cancer , endometrial carcinomas (Takai et al., 2001b) , colorectal cancer Takahashi et al., 2003) , ovarian cancer (Takai et al., 2001a; Weichert et al., 2004a) , pancreatic cancer (Gray et al., 2004), prostate carcinomas (Weichert et al., 2004b) and in papillary carcinomas (Ito et al., 2004) . Furthermore, there is a significant correlation between the percentage of Plk1-positive cells and the histological grade of ovarian cancer (Takai et al., 2001a) . Moreover, different evaluations revealed that Plk1 expression correlates to the metastatic potential of tumors (Kneisel et al., 2002) and to the prognosis of cancer patients Yuan et al., 1997; Takai et al., 2001a) .
A study describing the overexpression of Plk1 in the majority of tumor cell lines further underlined the hypothesis that Plk1 overexpression might lead to enhanced proliferation and thus to cellular transformation (Simizu and Osada, 2000) . Consistently, in tumor cell lines with lower Plk1 levels mutations within the Cterminus of Plk1 could be identified that inhibit the Hsp90 interaction, which is known to stabilize Plk1 protein. These mutations are all located between aa 457 and 569, a region encompassing the PB2 (aa 511-592) (Cheng et al., 2003) , which is essential for the function of the PBD and for the correct subcellular localization of Plk1 (Lee et al., 1998; Elia et al., 2003) .
Taken together, Plk1 expression and activity are tightly controlled during the cell cycle. Most tumors and tumor cell lines harbor aneuploid or polyploid phenotypes. These are the kind of abnormalities that could result partly from abnormal Plk1 functions. Evidence for Plk1 overexpression as a cause and not as a result of oncogenic transformation came from a study demonstrating that enforced expression of murine Plk1 in NIH3T3 cells confers a transformed phenotype as shown by the ability of these cells to form foci capable to grow in soft agar and even more importantly to form tumors in nude mice (Smith et al., 1997) . The model of Plk1 as a promoter of oncogenic transformation was recently supported by a study of van Vugt and coworkers reporting that depletion of Plk1 in U2OS osteosarcoma cells completely abrogated the ability of these cells to form colonies, further supporting the model that Plk1 is a key player for cellular proliferation and its overexpression contributes to oncogenic transformation (van Vugt et al., 2004) .
Interestingly, in contrast to Plk1 the expression of Plk3, which was originally named Prk and identified as an immediate-early gene inducible by serum, correlates negatively with the development of certain types of cancers (Li et al., 1996) . Plk3 is downregulated in HNSCC , in rat colon tumors (Dai et al., 2002a) and in lung carcinomas (Li et al., 1996) . In contrast, Plk3 and Plk1 were found to be overexpressed in highly proliferating malignant epithelial ovarian tumors. This overexpression is associated with enhanced mitosis and worse patients prognosis (Weichert et al., 2004a) . However, the observation that Plk3 is activated in response to DNA damage supports the hypothesis that Plk3 acts as a tumor suppressor protein. Mutational inactivation of Plk3 appears to be a rare event in lung cancer, because neither nonsense nor missense mutations could be detected in an analysis of 40 lung tumor cell lines (Wiest et al., 2001) . Thus, reduced expression levels of Plk3 rather than mutations of the Plk3 gene seem to participate in tumor development. Ectopic expression of wild-type Plk3 but not a kinasedeficient version is able to reduce the proliferation rate of transformed fibroblasts . Plk3 seems to negatively regulate oncogenesis as demonstrated by enforced expression of Plk3, leading to rapid cell cycle arrest and apoptosis (Conn et al., 2000; Wang et al., 2002) . Beyond its role in cell cycle progression, Plk3 seems to have additional functions in noncycling cells. It has been reported that Plk3 might be part of the signaling network controlling cellular adhesion since it is overexpressed in adherent versus nonadherent macrophages and interacts with the calcium-and integrinbinding protein (CIB), which is involved in integrin signaling pathways (Holtrich et al., 2000) . Plk2, like Plk3, associates with CIB and both kinases have been implicated in long-term synaptic plasticity and thus may perform postmitotic functions (Kauselmann et al., 1999) .
Expression of Plk2 mRNA is rapidly induced in human thyroid cells upon X-ray irradiation. A radiation-responsive element has been identified as p53RE, a p53-binding homology element, in the basal promoter region of Plk2 (Shimizu-Yoshida et al., 2001) .
Controversial data exist for the expression profile of Plk4. While Karn and co-workers observed a Plk4 expression that is restricted to the testis and thymus (Karn et al., 1997) , Fode and co-workers found that expression of Plk4 like Plk1 is associated with mitotic and meiotic cell division (Fode et al., 1994) . Moreover, it has been reported that Plk4 is overexpressed in colorectal tumors and might contribute to chromosomal instability . Further studies are required to elucidate the role of Plk4 in oncogenesis in more detail.
Plks and tumor suppressor genes
Several interacting partners of Plk1 have been identified that are encoded by tumor suppressor genes. This finding strengthens the link between Plks and oncogenesis. Over 50% of human cancers contain mutations in the gene coding for p53, which is a well-characterized tumor suppressor gene (Levine, 1997) . It has been reported that Plk1 is able to phosphorylate the p53 protein in vitro (Xie et al., 2001) . A recent study revealed that Plk1 indeed physically binds to the DNA-binding region of the tumor suppressor p53 in mammalian cultured cell. Expression of exogenous Plk1 and p53 in p53-deficient lung carcinoma H1299 cells greatly decreased the p53-mediated transcription of the p53-responsive p21WAF1, MDM2 and BAX promoters, whereas the kinase-deficient mutant form of Plk1 failed to reduce the transcriptional activity of p53. In addition, Plk1 inhibited the proapoptotic function of p53 in H1299 cells (Ando et al., 2004) . Interestingly, the exposure of human neuroblastoma-derived SH-SY5Y cells to cisplatin leads to a remarkable accumulation of p53, which is strongly associated with a significant downregulation of the endogenous Plk1 both at mRNA and protein levels, suggesting that Plk1 is closely involved in the regulation of p53 stability and thereby modulates its activity (Ando et al., 2004) . The data are consistent with a previous report demonstrating that p53 activity is significantly stabilized in Plk1-depleted cells . Although Ando and coworkers were not able to identify the exact phosphorylation site in p53 by Plk1, the results still demonstrated that p53 is a target of Plk1. Its function is inhibited through the physical interaction with Plk1, suggesting that Plk1-mediated negative regulation of p53 might be a fundamental mechanism for the role of Plk1 in oncogenesis. Further studies are required for exploring the relationship between Plks and the p53 suppressor family.
It has been shown that p53 plays a direct role in response to spindle damage during mitosis through the regulation of Plk2 (Burns et al., 2003) . Plk2 is transcriptionally regulated by p53 (Shimizu-Yoshida et al., 2001; Burns et al., 2003) and expression of Plk2 is induced in a p53-dependent manner in response to irradiation (Burns et al., 2003) . In the presence of mitotic inhibitors, silencing of Plk2 by siRNA was followed by an increase in apoptosis similar to what is observed when p53 is mutated. Apoptosis occurred during mitosis and not in G 1 , indicating that p53 seems to respond to a mitotic checkpoint. Burns and coworkers suggest a role for p53 in activating Plk2 to prevent mitotic catastrophe following spindle damage (Burns et al., 2003) . This observation reveals a novel mechanism by which p53 prevents genomic instability. While Plk2 is activated by the spindle checkpoint during mitosis, Plk3 is activated by the DNA damage checkpoint. Both kinases contribute to cell cycle arrest in G 2 phase and/or mitosis. In contrast to Plk1, Plk3-mediated phosphorylation of p53 at Ser-20 is supposed to stabilize p53, which links Plk3 to the DNA damage checkpoint and apoptosis (Xie et al., 2001) . Taken together, these observations indicate an antiproliferative impact of Plk2 and Plk3 during mitosis.
Phosphorylation of the breast cancer susceptibility protein BRCA2 by Plk1 occurs during mitosis (Lin et al., 2003; Lee et al., 2004) . The phosphorylation of BRCA2 is inhibited by DNA damage, which is consistent with the finding that Plk1 activity is negatively regulated by DNA damage (Smits et al., 2000) . BRCA2 interacts with the p300/CBP (CREB-binding protein)-associated factor (P/CAF). One potential function of this complex in G 2 phase is to prevent premature entry into mitosis. The Plk1-mediated phosphorylation of BRCA2 leads to dissociation of this complex (Lin et al., 2003) . Interestingly, when cells progress to mitosis, BRCA2 localizes to condensing chromosomes (Marmorstein et al., 2001) . Whether this chromosomal localization of BRCA2 is mediated by P/CAF and contributes to the tumor suppressor function during mitosis is still unknown.
Chk2, a cell cycle checkpoint kinase that is implicated in DNA repair processes, is also considered as a tumor suppressor protein. Mouse Chk2À/À ES cells are defective in the maintenance of G 2 arrest and stabilization of p53 for G 1 arrest (Hirao et al., 2000) .
Interestingly, a truncated version of Chk2 lacking kinase activity leads to increased breast cancer risk in patients carrying wild-type BRCA1 and BRCA2 (MeijersHeijboer et al., 2002) . In contrast, this Chk2 variant does not confer increased cancer risk in patients exhibiting additional BRCA1 or BRCA2 mutations, indicating that Chk2 participates in the same pathway as BRCA proteins do. Chk2 and Plk1 have been shown to colocalize at centrosomes in early mitosis and to the mid-body in late mitosis (Tsvetkov et al., 2003) . Plk1 is able to phosphorylate Chk2 at Thr-68, a site that is normally phosphorylated by ataxia telangiectasia mutated (ATM) in response to ionizing radiation, leading to its activation . It has been suggested that this Plk1-mediated phosphorylation of Chk2 contributes to a crosstalk between DNA damage checkpoints and mitotic regulation. While the detailed function of this interaction still needs to be further elucidated, the phosphorylation of Chk2 by Plk3 has been shown to fully activate Chk2 in response to DNA damage (Bahassi el et al., 2002) . It has been demonstrated that Plk3 itself is phosphorylated by the tumor suppressor ATM, leading to increased Plk3 kinase activity. Whereas Plk1 is inhibited in response to DNA damage, Plk3 is activated suggesting that both kinases have opposing roles in checkpoint control (Xie et al., 2001) . Furthermore, Plk1 promoter activity is repressed by the retinoblastoma (RB) tumor suppressor pathway (Gunawardena et al., 2004) . While Plk1 that communicates with Chk2 is also downregulated by BRCA1 and RB, Plk3 is able to phosphorylate and thereby activates tumor suppressor proteins like Chk2. Phosphorylation of p53 by Plk3 occurs at Ser-20, which is known to be involved in the stabilization of the protein after DNA damage (Xie et al., 2001) .
To prevent oncogenic transformation, cells have to maintain the function of tumor suppressor molecules, which in turn antagonize or inhibit oncogenes leading to controlled proliferation. Plk1 is a target of the adriamycin-induced DNA damage checkpoint and it has been suggested that Chk1, which is considered to be a tumor suppressor is involved in this process (Smits et al., 2000) . Activation of this pathway leads to the reduction of Plk1 activity but does not seem to affect Plk1 protein levels. Furthermore, this pathway does not only mediate G 2 /M arrest but also mitotic arrest. However, suppression of Plk1 mRNA transcription after ionizing radiationinduced DNA damage is mediated by BRCA1 (Ree et al., 2003) . Furthermore, this Plk1 downregulation also seems to be dependent on Chk1 activity. ATM, ATR and Chk2 can activate BRCA1, which in turn is essential for the activation of Chk1 (Yarden et al., 2002) . Thus, a network of tumor suppressor proteins seems to control downstream pathways and furthermore enables lateral communication between different pathways to ensure proper inhibition of crucial mitosis-promoting enzymes like Plk1. It is interesting to note that overexpression of CT-BRCA1, which functions in a dominant-negative manner, leads to loss of the G 2 /M checkpoint normally induced by the spindle poison colchicine (Larson et al., 1997) . Thus, deregulation of tumor suppressor genes like BRCA1 and RB might lead to enhanced expression of Plk1 further promoting tumorigenesis.
ATM and ATM-and Rad3 related (ATR) are two tumor suppressor proteins with phosphotransferase activity. ATM plays a very important role in the linkage of DNA damage and the induction of a subsequent cell cycle arrest, whereas ATR responds to other types of damage (Zhou and Elledge, 2000) . DNA damageactivated ATM positively regulates the activation of other checkpoint kinases, like Chk1 and Chk2 Gatei et al., 2003) , and phosphorylates p53, MDM-2 and BRCA1 (Banin et al., 1998; Canman et al., 1998; Cortez et al., 1999; Khosravi et al., 1999) . At the G 2 -DNA damage checkpoint inhibition of Plk1 activity depends on ATM/ATR activity (van Vugt et al., 2001) . However, a recent study reported that dephosphorylation of Plk1 after mitotic DNA damage is independent of the ATM pathway (Yuan et al., 2004b) . Thus, inhibition of Plk1 after DNA damage might be regulated in different ways: (i) interphase DNA damage leads to Plk1 inhibition in an ATM-/ATR-dependent manner. (ii) If DNA damage occurs in cells that already proceeded into mitosis, Plk1 inhibition is ATM/ATR independent. Further studies are required to elucidate the regulation of Plk1 activity followed DNA damage in human tumors.
Taken together, Plk1 interacts with several tumor suppressor proteins (Figure 1) . On one the hand, Plk1 phosphorylates p53, Chk2 and BRCA2 possibly to promote mitotic progression. On the other hand, Plk1 is inhibited by several checkpoint pathways. Tumor suppressor proteins like ATM, ATR, BRCA1 and Chk1 are involved in this inhibition. Thus, Plk1 and tumor suppressor proteins are acting in an antagonistic manner. An imbalance between these proliferationregulating signals may contribute to oncogenesis.
Therapeutic approaches targeting Plks
As discussed above, Plk1 is closely correlated with cellular proliferation and is highly expressed in various human primary tumors. The Plk1 level is associated with tumor progression and is considered as a marker for poor prognosis in tumor patients. The deregulation of Plk1 promotes elevated cell proliferation by inhibiting tumor suppressors and over-riding cellular checkpoints. Furthermore, deregulation of Plk1 generates abnormal centrosomes as well as mitotic spindles and impairs cytokinesis. The intriguing evidence of Plk in oncogenesis comes from an experiment in which enforced expression of murine Plk1 in NIH3T3 cells induced tumor formation in nude mice (Smith et al., 1997) . Still, genetic evidence for a direct role of Plk1 in human tumorigenesis is lacking. Nevertheless, the data from different systems strongly suggest that Plk1 is involved in tumor development and is regarded as an attractive target for tumor intervention therapies.
Indeed, many strategies were applied to downregulate the activity of Plk1. Interestingly, microinjection of Plk1 antibodies induced mitotic catastrophe in HeLa cells, whereas normal human diploid fibroblasts Hs68 arrested transiently in the G 2 phase of the cell cycle (Lane and Nigg, 1996) . These results support the notion that inhibition of Plk1 might be a powerful tool to target cancer cells specifically, since nontransformed cells that should exhibit intact checkpoint pathways are less affected. Moreover, expression of dominant-negative Plk1 (dnPlk1) via an adenoviral vector induces programmed cell death in most tumor cells but not in normal human mammary epithelial cells (HMECs) (Cogswell et al., 2000) . The finding that Plk1 expression is elevated in numerous human tumors implies that interference with Plk1 expression or function is likely to be more detrimental to tumor cells than to normal cells. Inhibition of Plk1 activity blocked both mitotic phosphorylation of Cdc25C and activation of Cdk1 but selectively killed tumor cells, indicating that mitotic catastrophe can be induced by dnPlk1 independent of the action of the mitotic activators Cdc25C and Cdk1 (Cogswell et al., 2000) . Based on this observation and similar results from Xenopus, it has been hypothesized that silencing of Plk1 might lead to the inhibition of Cdc25C and cyclin B1/Cdk1 followed by G 2 /M arrest and apoptosis in prostate cancer (Ahmad, 2004) . Nevertheless, another study reported that dnPlk1 induces activation of Cdk1 (Seong et al., 2002) . However, in both cases interference with Plk1 functions led to severe defects in mitotic cell division and mitotic catastrophe. Thus, targeting mitotic key regulators like Plk1 or Cdk1/cyclin B1 might become a powerful strategy to inhibit cancer cell proliferation. Specific inhibition of Cdk1/cyclin B1 by siRNAs directed against cyclin B1 had been shown to inhibit tumor cell proliferation and induced apoptosis in cancer cells, whereas primary human umbilical vein endothelial cells were hardly affected (Yuan et al., 2004a) . Application of antisense oligodeoxynucleotides (ASOs) to Plk1 resulted in effective inhibition of Plk1 expression in tumor cell lines, leading to loss of cell viability and exhibited antitumor activity in A549 xenografts in nude mice (Elez et al., 2000; Spankuch-Schmitt et al., 2002b) . Furthermore, these ASOs did not inhibit viability and growth of primary cells (Elez et al., 2000) . More pronounced cellular defects were induced by using siRNAs directed against Plk1, which also exhibited antiproliferative effects in tumor cell lines, while HMECs were much less sensitive than cancer cells to Plk1-targeted siRNAs (Spankuch-Schmitt et al., 2002a) . However, the effects observed after the use of different approaches targeting Plk1 differ. While transfection of dnPlk1 inhibits Cdk1 activation, the use of RNAi directed against Plk1 led to enhanced Cdk1 activity (Cogswell et al., 2000; Liu and Erikson, 2002) . The different results observed might be due to a strong downregulation of Plk1 by RNAi versus an overexpression of dnPlk1 correlated with high abundance of functional C-termini including the PBD. It seems that Plk1 depletion by using siRNAs rather affects the progression of cells through mitosis than entry into mitosis since it leads to elevated Cdk1 activity and prevents degradation of cyclin B1 (Liu and Erikson, 2002) . This is consistent with the finding that inhibition of Plk1 leads to mitotic catastrophe (Cogswell et al., 2000) . This notion is further supported by the observation that Plk1 depletion inhibits the separation of sister chromatids and leads to failure of cytokinesis (Liu and Erikson, 2002) . Interestingly, similar results were obtained by using the PB (PB1) of Plk1 fused to an antennapedia peptide, indicating that the functional PB motif is important for the function of Plk1 (Yuan et al., 2002b) . Internalization of this peptide into tumor cells also led to the inhibition of proliferation. Furthermore, mitotic arrest was observed, which was followed by incomplete cytokinesis and apoptosis. These effects were hardly observed in HMEC.
Furthermore, vector-driven depletion of Plk1 induced G 2 /M arrest and apoptosis . It was observed that this Plk1 depletion led to DNA damage, which was followed by stabilization of p53 and presumably caused subsequent ATM activation. Plk1-depleted cells were hypersensitive to ATM inhibition and treatment of Plk1-depleted cells with ATM inhibitors potentiated the lethality of Plk1 depletion . The checkpoint kinase ATM links DNA damage to G 2 arrest, indicating that in normal cells, which are arrested in G 2 after Plk1 antibody injection, this ATM-mediated checkpoint might protect the cells against mitotic catastrophe. In contrast, the antibody injection allows immortalized HeLa cells to proceed incorrectly into mitosis followed by mitotic catastrophe and apoptosis (Lane and Nigg, 1996) . These results encourage utilization of methods like RNAi to target tumor cells specifically by Plk1 depletion to fight cancer in humans. The growth-inhibitory potential of RNAi against Plk1 was extended to the use of U6-driven shRNAs directed against human Plk1 in mice harboring human xenograft tumors, revealing that siRNA is suitable to inhibit neoplastic progression in vivo (Spankuch et al., 2004) .
A recent study further elucidated the molecular mechanisms by which Plk1 depletion affects mitotic cell division in human cells. Van Vugt and co-workers clearly demonstrated that the majority of cells depleted of Plk1 by RNAi enter mitosis with normal kinetics, indicating that Plk1 might be dispensable for human cells to enter mitosis (van Vugt et al., 2004) . Furthermore, this study revealed that the majority of cells depleted of Plk1 arrest in prometaphase. Plk1 depletion did not prevent microtubule-nucleation and microtubule-kinetochore attachments, which were readily observed. The failure of Plk1-depleted cells to align their chromosomes and to establish a bipolar spindle is caused by a defect in centrosome maturation. Survivin is required to maintain checkpoint-mediated arrest in response to lack of tension at the kinetochores. Interestingly, while depletion of Plk1 led to mitotic arrest, codepletion of survivin and Plk1 allows cells to exit mitosis (van Vugt et al., 2004) . This indicates that Plk1 depletion does not interfere with microtubule attachment to kinetochores but blocks the build-up of tension on the kinetochores.
Recently, it has been shown that expression of the Cterminus of Plk1, which contains both PBs and thus acts in a dominant-negative manner leads to the activation of a Mad2-dependent spindle checkpoint pathway (Seong et al., 2002) . Consistently, the mitotic arrest induced by Plk1 depletion could be rescued by codepletion of Plk1 with either spindle checkpoint proteins BubR1 or Mad2, thereby enabling the cells to exit mitosis (van Vugt et al., 2004) . Thus, Plk1 depletion leads to the activation of the spindle assembly checkpoint, suggesting that the enhanced activity of cyclin B1/Cdk1 complexes in Plk1-depleted cells is not due to direct inhibition of APC functions since the authors reported that the activation of APC Cdc20 after Plk1 depletion is unperturbed in human cells. Thus, the functions of human Plk1 differ from Xenopus Plx1 (Descombes and Nigg, 1998) . Despite the highly conserved functions of Plks their roles in different species vary.
The studies described above help to elucidate the mechanisms by which therapeutical approaches targeting Plk1 contribute to the inhibition of cellular proliferation and oncogenic transformation. A better understanding of the effect of inhibitors like dnPlk1, RNAi or PB peptides is of importance to attack cellular proliferation specifically in human cancer. Still, the possible side effects occurring by Plk1 depletion in the whole organism need to be investigated, especially in normal proliferating tissues. If normal tissues are hardly affected by Plk1 depletion, it would be of special interest to investigate the potential of Plk1 inhibition as a novel tool in chemoprevention, since Plk1 depletion could be able to eliminate cells with oncogenic potential before they undergo further oncogenic transformation.
Conclusion
Overexpression of Plk1 is a common feature in most human tumors. Plk1 promotes mitotic cell division and also contributes to accelerated proliferation in mammalian cells. Silencing of Plk1 functions inhibits cellular proliferation and leads to mitotic arrest accompanied by mitotic catastrophe. Furthermore, overexpression of Plk1 enables tumor cells to over-ride mitotic checkpoints leading to genetic instability, which in turn promotes the transformation of mammalian cells. Thus, among mammalian Plks, Plk1 exhibits the most striking promotion of neoplastic transformation. In contrast, other members of the Plk family like Plk3 are activated by mitotic checkpoints and seem to inhibit oncogenic transformation. Given the highly conserved structure of Plks, it will be important to develop therapeutic approaches for specific targeting of Plk1. Since deregulation of Plk1 seems to be an early event in the oncogenic transformation of human cells, these approaches might be helpful to fight early cancer development.
Abbreviations Plk1, Polo-like kinase 1; PB, polo box; PBD, polo-box domain; APC, anaphase-promoting complex; dnPlk1, dominant-negative Plk1.
